Celularity Inc (CELU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celularity Inc (CELU) has a cash flow conversion efficiency ratio of 0.207x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.16 Million) by net assets ($-20.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CELU net asset quality score to measure how much of total assets are equity-financed.
Celularity Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Celularity Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Celularity Inc to evaluate the quality of earnings relative to operating cash generation.
Celularity Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celularity Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Teck Guan Perdana Bhd
KLSE:7439
|
0.172x |
|
RHYTHM Biosciences Ltd
AU:RHY
|
-1.037x |
|
Wilton Resources Inc
V:WIL
|
-1.093x |
|
LQR House Inc
NASDAQ:YHC
|
-0.051x |
|
Oxford Instruments PLC
LSE:OXIG
|
0.155x |
|
Sanginita Chemicals Limited
NSE:SANGINITA
|
0.017x |
|
ZICOM Group Ltd
AU:ZGL
|
0.499x |
|
OHEIM INT Co.Ltd
KQ:309930
|
0.298x |
Annual Cash Flow Conversion Efficiency for Celularity Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Celularity Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see CELU stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.84 Million | $-6.40 Million | -0.724x | +23.31% |
| 2023-12-31 | $40.96 Million | $-38.69 Million | -0.944x | -36.25% |
| 2022-12-31 | $198.90 Million | $-137.88 Million | -0.693x | +37.40% |
| 2021-12-31 | $99.42 Million | $-110.10 Million | -1.107x | +67.21% |
| 2020-12-31 | $18.71 Million | $-63.19 Million | -3.377x | -42306.64% |
| 2019-12-31 | $137.86 Million | $-1.10 Million | -0.008x | -284.56% |
| 2018-12-31 | $-125.85K | $-543.00 | 0.004x | -- |
About Celularity Inc
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioB… Read more